| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -60,825 | -20,154 | -59,100 | -139,706 |
| Share-based compensation expense | 6,930 | 11,653 | 8,771 | 19,040 |
| Depreciation and amortization | 1,129 | 1,336 | 1,756 | 3,330 |
| Deferred income tax benefit | -241 | 843 | -46 | -1,647 |
| Research and development incentives receivable | 6,040 | -31,287 | 7,614 | 20,781 |
| Prepaid expenses and other assets | -191 | -4,130 | 1,375 | 8,571 |
| Operating lease right-of-use assets | -1,111 | -1,190 | -1,172 | -2,235 |
| Accounts payable | -3,838 | -2,881 | -5,070 | 1,080 |
| Accrued expenses and other current liabilities | -2,353 | 2,000 | 1,121 | 972 |
| Operating lease liabilities | -1,283 | -1,410 | -1,390 | -2,656 |
| Deferred revenue | -706 | -47,340 | -9,398 | -12,452 |
| Net cash used in operating activities | -65,925 | -19,346 | -71,173 | -159,156 |
| Purchases of property and equipment | 713 | 574 | 674 | 1,102 |
| Net cash used in investing activities | -713 | -574 | -674 | -1,102 |
| Proceeds from the exercise of share options and settlement of restricted share units | 12 | 33 | 1 | 3 |
| Payments of finance lease obligations | 66 | 48 | 31 | 89 |
| Net cash used in financing activities | -54 | -15 | -30 | -86 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -1,944 | -222 | -1,249 | 2,275 |
| Net decrease in cash, cash equivalents and restricted cash | -68,636 | -20,157 | -73,126 | -158,069 |
| Cash, cash equivalents and restricted cash at beginning of period | 628,715 | 648,872 | 880,067 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 560,079 | 628,715 | 648,872 | NaN |
BICYCLE THERAPEUTICS PLC (BCYC)
BICYCLE THERAPEUTICS PLC (BCYC)